Literature DB >> 12667946

Human chagasic IgGs bind to cardiac muscarinic receptors and impair L-type Ca2+ currents.

Ciria Carolina Quintero Hernández1, Luciane Claudia Barcellos, Luis Eduardo Díaz Giménez, Rafael Armando Bonfante Cabarcas, Simone Garcia, Roberto Coury Pedrosa, Jose Hamilton Matheus Nascimento, Eleonora Kurtenbach, Masako Oya Masuda, Antonio Carlos Campos de Carvalho.   

Abstract

OBJECTIVES: Antibodies against cardiac G protein-coupled receptors have been reported in sera from chronic chagasic patients (CChP) and other non-parasitic cardiomyopathies, but the effects and underlying mechanism of interaction between these antibodies and heart cells are not fully established. To address this point, binding of antibodies purified from sera of CChP patients and normal blood donors (NBD) to cardiac muscarinic acetylcholine receptors (mAChR) and their effect on L-type Ca(2+) currents were examined. METHODS AND
RESULTS: Saturation [3H]NMS binding experiments with porcine atrial membranes showed that B(max) in the presence of CChP-immunoglobulin G (IgG) decreased from 280.2+/-16.08 fmol/mg (control) to 91.00+/-5.98 fmol/mg, with no apparent change in K(D), while NBD-IgG did not significantly alter these parameters. At the single channel level, CChP-IgG decreased both the fast and slow mean open times and P(o) (from 0.074+/-0.023 to 0.025+/-0.007) without changes in single channel conductance. I/V plots of isoproterenol-stimulated whole-cell L-type Ca(2+) currents (I(Ca)) from rabbit ventricular cardiomyocytes showed a significant reduction in peak I(Ca) during perfusion with CChP-IgG (at 0 mV: from 10.61+/-2.97 to 8.45+/-2.54 pA/pF). NBD-IgGs had no effect on I(Ca). A CChP-IgG purified against a peptide corresponding to the second extracellular loop of the M(2) receptor also impaired L-type Ca(2+) currents. All effects of CChP-IgG were blocked by atropine.
CONCLUSIONS: Our results show that antibodies from CChP bind to mAChR in a non-competitive manner and are able to activate the receptor in an agonist-like form resulting in L-type Ca(2+) current inhibition.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12667946     DOI: 10.1016/s0008-6363(02)00811-8

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  10 in total

Review 1.  Role of autoantibodies in the physiopathology of Chagas' disease.

Authors:  Emiliano Horacio Medei; José Hamilton Matheus Nascimento; Roberto Coury Pedrosa; Antônio Carlos Campos de Carvalho
Journal:  Arq Bras Cardiol       Date:  2008-10       Impact factor: 2.000

2.  Treatment with benznidazole during the chronic phase of experimental Chagas' disease decreases cardiac alterations.

Authors:  Simone Garcia; Carolina O Ramos; Juliana F V Senra; Fabio Vilas-Boas; Maurício M Rodrigues; Antonio C Campos-de-Carvalho; Ricardo Ribeiro-Dos-Santos; Milena B P Soares
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

3.  Modulation of M(2) muscarinic receptor-receptor interaction by immunoglobulin G antibodies from Chagas' disease patients.

Authors:  S P Beltrame; S R Auger; C R Bilder; C I Waldner; J C Goin
Journal:  Clin Exp Immunol       Date:  2011-03-10       Impact factor: 4.330

4.  Activating autoantibodies to the beta-1 adrenergic and m2 muscarinic receptors facilitate atrial fibrillation in patients with Graves' hyperthyroidism.

Authors:  Stavros Stavrakis; Xichun Yu; Eugene Patterson; Shijun Huang; Sean R Hamlett; Laura Chalmers; Reji Pappy; Madeleine W Cunningham; Syed A Morshed; Terry F Davies; Ralph Lazzara; David C Kem
Journal:  J Am Coll Cardiol       Date:  2009-09-29       Impact factor: 24.094

5.  Targeting individual GPCRs with redesigned nonvisual arrestins.

Authors:  Luis E Gimenez; Sergey A Vishnivetskiy; Vsevolod V Gurevich
Journal:  Handb Exp Pharmacol       Date:  2014

6.  Autoantibodies enhance agonist action and binding to cardiac muscarinic receptors in chronic Chagas' disease.

Authors:  Ciria C Hernandez; Jose H Nascimento; Elen A Chaves; Patricia C Costa; Masako O Masuda; Eleonora Kurtenbach; Antonio C Campos DE Carvalho; Luis E Gimenez
Journal:  J Recept Signal Transduct Res       Date:  2008       Impact factor: 2.092

7.  Chagas' disease: IgG isotypes against cytoplasmic (CRA) and flagellar (FRA) recombinant repetitive antigens of Trypanosoma cruzi in chronic Chagasic patients.

Authors:  A F A Verçosa; V M B Lorena; C L Carvalho; M F A D Melo; M G A Cavalcanti; E D Silva; A G P Ferreira; V R A Pereira; W V Souza; Y M Gomes
Journal:  J Clin Lab Anal       Date:  2007       Impact factor: 2.352

8.  Electrophysiological and pharmacological evaluation of the nicotinic cholinergic system in chagasic rats.

Authors:  Rafael Bonfante-Cabarcas; Erlymar López Hincapié; Eliezer Jiménez Hernández; Ruth Fonseca Zambrano; Lady Ferrer Mancini; Marcos Durand Mena; Claudina Rodríguez-Bonfante
Journal:  BMC Pharmacol Toxicol       Date:  2013-01-07       Impact factor: 2.483

Review 9.  Drug-like actions of autoantibodies against receptors of the autonomous nervous system and their impact on human heart function.

Authors:  L R Herda; S B Felix; F Boege
Journal:  Br J Pharmacol       Date:  2012-06       Impact factor: 8.739

10.  Participation of Central Muscarinic Receptors on the Nervous Form of Chagas Disease in Mice Infected via Intracerebroventricular with Colombian Trypanosoma cruzi Strain.

Authors:  Gabriela Maira Pereira de Assis; Micheline Freire Donato; Matheus Marques Milagre; Samantha Ribeiro Béla; Mayra Fernanda Ricci; Luara Augusta Batista; Maria Elena de Lima; Fabrício de Araujo Moreira; Rosa Maria Esteves Arantes; Marta de Lana
Journal:  Pathogens       Date:  2021-01-25
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.